Valuation: Celsion Corporation

Market Cap 89.78L 77.51L 72.72L 66.23L 1.25Cr 86Cr 1.26Cr 8.52Cr 3.34Cr 43Cr 3.37Cr 3.3Cr 143.06Cr P/E 2026 *
-0.67x
P/E 2027 * -0.86x
Enterprise Value 89.78L 77.51L 72.72L 66.23L 1.25Cr 86Cr 1.26Cr 8.52Cr 3.34Cr 43Cr 3.37Cr 3.3Cr 143.06Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+4.80%+3.44%+70.64%+109.32% 7.33TCr
-1.54%+12.39%+46.81%+87.61% 6.2TCr
+3.70%-4.77%+0.41%+484.07% 2.8TCr
+5.46%+5.83%+56.97%+21.50% 2.41TCr
-1.60%-1.29%-19.31%-19.10% 2.3TCr
-6.00%+6.02%+244.39%+430.80% 1.83TCr
+0.74%+5.67%+39.70%-14.22% 1.95TCr
+3.64%+2.46%+21.20%+556.36% 1.59TCr
+2.11%-1.21%+36.57%+149.14% 1.3TCr
Average +1.25%+1.06%+55.26%+200.61% 3.08TCr
Weighted average by Cap. +1.59%+3.14%+54.45%+164.21%

Financials

2026 *2027 *
Net sales - -
Net income -1.48Cr -1.28Cr -1.2Cr -1.09Cr -2.06Cr -141.73Cr -2.08Cr -14Cr -5.51Cr -71Cr -5.57Cr -5.44Cr -236.2Cr -1.93Cr -1.67Cr -1.56Cr -1.42Cr -2.68Cr -184.64Cr -2.72Cr -18Cr -7.18Cr -93Cr -7.25Cr -7.09Cr -307.71Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-